Clinical trials update from the Annual Scientific Session of the American College of Cardiology 2006
The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,
Management and Avoidance (CHARISMA) trial showed that the addition of clopidogrel to …
Management and Avoidance (CHARISMA) trial showed that the addition of clopidogrel to …
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High …
BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …
Cost‐effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial
Objective: To determine the incremental cost‐effectiveness of clopidogrel plus aspirin (C+ A)
compared with aspirin (A) alone during the Clopidogrel for High Atherothrombotic Risk and …
compared with aspirin (A) alone during the Clopidogrel for High Atherothrombotic Risk and …
Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin?
MR Bakhru, DL Bhatt - Cleveland clinic journal of medicine, 2008 - europepmc.org
The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management,
and Avoidance (CHARISMA) study (N Engl J Med 2006; 354: 1706-1717, J Am Coil Cardiol …
and Avoidance (CHARISMA) study (N Engl J Med 2006; 354: 1706-1717, J Am Coil Cardiol …
Antiplatelet therapy in populations at high risk of atherothrombosis.
Atherothrombosis is the most common cause of an acute ischemic event. Antiplatelet agents
form the cornerstone of atherothrombosis prevention. The purpose of this article is to review …
form the cornerstone of atherothrombosis prevention. The purpose of this article is to review …
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies
Clopidogrel has been evaluated in clinical trials that included cardiovascular patients with
different risk levels for a cardiovascular event. We reviewed the results of the Clopidogrel vs …
different risk levels for a cardiovascular event. We reviewed the results of the Clopidogrel vs …
Clinical evaluation of clopidogrel across the whole spectrum of indications: primary and secondary prevention of coronary artery disease
EI de Oliveira, DL Bhatt - European heart journal supplements, 2006 - academic.oup.com
Clopidogrel has been evaluated across the spectrum of secondary and primary prevention.
Initially, the CAPRIE trial randomized patients with recent myocardial infarction, ischemic …
Initially, the CAPRIE trial randomized patients with recent myocardial infarction, ischemic …
[引用][C] Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis.
KA Ballew - Evidence-based Medicine, 2006 - europepmc.org
Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death
in high risk atherothrombosis. - Abstract - Europe PMC Sign in | Create an account …
in high risk atherothrombosis. - Abstract - Europe PMC Sign in | Create an account …
Aspirin plus clopidogrel vs aspirin alone for preventing cardiovascular events among patients at high risk for cardiovascular events
MP Donadini, M Bellesini, A Squizzato - JAMA, 2018 - jamanetwork.com
Clinical Question Among patients at high risk for or with established cardiovascular disease
(ie, history of peripheral artery disease, stroke, or coronary artery disease without a coronary …
(ie, history of peripheral artery disease, stroke, or coronary artery disease without a coronary …
Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease …
J Chen, C Shi, EM Mahoney, ES Dunn, S Rinfret… - Canadian Journal of …, 2011 - Elsevier
Abstract Background The Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance (CHARISMA) trial found a statistically significant …
Stabilization, Management, and Avoidance (CHARISMA) trial found a statistically significant …